This study randomized 461 patients with resectable stage IIA (> 4 cm) to IIIB (N2 node stage, single- or multistation) NSCLC (AJCC 8th edition) with no known EGFR mutations or ALK translocations to either neoadjuvant nivolumab or placebo with platinum-doublet chemotherapy for 4 cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. Here, EGFR is linked to non-small cell lung carcinoma.